Research › Fact Sheets › MRK

MERCK & CO., INC.

LISTEDNYSE

SYMBOLMRK

SIC2834

STATE OF INC.NJ

FISCAL YEAR ENDSDecember 31

CIK310158

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	49,300	48.4
Stockholders' equity	52,606	51.6
Total capitalization	101,906	100.0

2,467,171,638 shares outstanding at 31 July 2026 (cover page of the 10-Q filed 7 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, incl. current maturities	49,300
Long-term debt, noncurrent	46,750
Current maturities	2,300

CAPITAL STOCK 12/31/25

Common shares authorized	6,500,000,000
Common shares issued	3,577,103,522
Treasury shares	1,102,476,756
Par or stated value per share ($)	0.5
Outstanding at 7/31/26	2,467,171,638

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	3.28	45.1
2024	3.12	46.3
2023	2.96	2114.3
2022	2.80	49.0
2021	2.64	51.4

HISTORY AND BUSINESS

HISTORY: Incorporated in New Jersey. Formerly known as SCHERING PLOUGH CORP (to 29 October 2009).

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	65,011	64,168	60,115
Cost of revenues	16,382	15,193	16,126
Research and development	15,789	17,938	30,531
Selling, general and administrative	10,733	10,816	10,504
Depreciation and amortization	3,045	2,104	1,828
Interest expense	1,357	1,271	1,146
Income before income taxes	21,067	19,936	1,889
Income taxes	2,804	2,803	1,512
Net income	18,254	17,117	365
Earned per share, diluted ($)	7.28	6.74	0.14
Dividends per share ($)	3.28	3.12	2.96

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Cash and equivalents	14,565	13,242
Receivables, net	11,775	10,278
Inventories	6,658	6,109
Total current assets	43,516	38,782
Property, plant and equipment, net	25,316	23,779
Goodwill	21,579	21,668
Total assets	136,866	117,106
Total current liabilities	28,327	28,420
Long-term debt	46,750	34,462
Stockholders' equity	52,606	46,313
Total liabilities and equity	136,866	117,106

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	65,011	–	18,254	28.1	7.28	3.28	16,472	4,112	12,360	136,866	84,204d	49,300	52,606	34.7	0.94
12/31/24	64,168	–	17,117	26.7	6.74	3.12	21,468	3,372	18,096	117,106	70,734d	37,100	46,313	37.0	0.80
12/31/23	60,115	–	365	0.6	0.14	2.96	13,006	3,863	9,143	106,675	69,040d	35,100	37,581	1.0	0.93
12/31/22	59,283	–	14,519	24.5	5.71	2.80	19,095	4,388	14,707	109,160	63,102d	30,700	45,991	31.6	0.67
12/31/21	48,704	–	13,049	26.8	5.14	2.64	13,122	4,448	8,674	105,694	67,437d	33,100	38,184	34.2	0.87
12/31/20	41,518	–	7,067	17.0	2.78	2.48	10,253	4,429	5,824	91,588	66,184d	31,800	25,317	27.9	1.26
12/31/19	39,121	–	9,843	25.2	3.81	2.26	13,440	3,369	10,071	84,397	58,396d	26,300	25,907	38.0	1.02
12/31/18	42,294	–	6,220	14.7	2.32	1.99	10,922	2,615	8,307	82,637	55,755d	25,100	26,701	23.3	0.94
12/31/17	40,122	–	2,394	6.0	0.87	1.89	6,451	1,888	4,563	87,872	53,303d	24,353	34,336	7.0	0.71
12/31/16	39,807	–	3,920	9.8	1.41	1.85	10,376	1,614	8,762	95,377	55,069d	24,574	40,088	9.8	0.61

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

Merck & Co., Inc.
CIK 310158 · EIN 22-1918501

PRINCIPAL OFFICE:

126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065
Tel.: 908-740-4000

INCORPORATED:

New Jersey

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 24 February 2026

FORMER NAMES:

Merck & Co. Inc.; SCHERING PLOUGH CORP

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

10/13/26	8-K	period 10/9/26
8/7/26	10-Q	period 6/30/26
8/4/26	8-K	period 8/4/26
5/28/26	8-K	period 5/26/26
5/22/26	8-K	period 5/22/26
5/4/26	10-Q	period 3/31/26
4/30/26	8-K	period 4/30/26
4/8/26	DEF 14A	period 5/26/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/24/26) · 10-K FY2024 (filed 2/25/25) · 10-K FY2023 (filed 2/26/24) · 10-K FY2022 (filed 2/24/23) · 10-K FY2021 (filed 2/25/22) · 10-K FY2020 (filed 2/25/21) · 10-K FY2019 (filed 2/26/20) · 10-K FY2018 (filed 2/27/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.